成立于 2017年的 本公司 百力司康作为 一家处于临床阶段的生物制药公司，致力于开发下一代抗体 偶联药物（ "ADC"），以解决目前肿瘤治疗中重要的未满足的需求。 截至目前，百力司康的 ADC管线 包含 四个处于临床阶段的候选药物 ——核心 产品 BB-1701是一 种 人 类 表 皮 生 长 因 子 受 体 2 （ "HER2" ） 靶 向 型 艾 立 布 林 ADC 候 选 药 物 ， 主 要 针 对 乳 腺 癌 （"BC"）、非小细胞肺癌（"NSCLC"）和潜在的其他HER2表达癌症。除核心产品外， 百力司康 还有其他三种处于临床阶段的 ADC：BB-1705（一种表皮生长因子受体（ "EGFR"）ADC）、 BB-1712 （一种抗B7同源蛋白3 （"B7-H3"）ADC）和BB-1709（一种分化簇73（"CD73"） ADC）， 且 所有管线资产都拥有完全的全球权利。 其中， BB-1701是全球临床阶段最靠前的针对或用于TOP1-i ADC经治患者的HER2 ADC候选药 物。 艾立布林作为一类在 70多个国家上市的肿瘤疗法，BB-1701 采用 艾立布林作为 ADC有效载 荷，利用艾立布林的 ...

据港交所6月29日披露，BlissBio Inc.(简称：百力司康)向港交所主板递交上市申请，高盛、华泰国际及 建银国际为联席保荐人。 除核心产品外，公司还有其他三种处于临床阶段的ADC：BB-1705(一种表皮生长因子受体 (EGFR)ADC)、BB-1712(一种抗B7同源蛋白3(B7-H3)ADC)和BB-1709(一种分化簇73(CD73)ADC)，它们 在广泛的适应症方面具有潜力。公司的所有管线资产都拥有完全的全球权利。 BB-1701是全球临床阶段最靠前的针对或用于TOP1-i ADC经治患者的HER2ADC候选药物。艾立布林作 为一类在70多个国家上市的肿瘤疗法，BB-1701采用艾立布林作为ADC有效载荷，利用艾立布林的多方 面作用机制、差异化耐药机制及其在全球70多个国家获批用于肿瘤治疗的临床验证疗效及安全性。根据 目前在美国、欧洲、日本及中国进行的2期研究，BB-1701已经显示具有令人鼓舞的疗效以及可控的安 全性，尤其是在260名患者中只有三例ILD(两例1级，一例2级)，较优赫得有所改善。 公司的内部化学、制造和控制(CMC)开发及制造能力在抗体开发、偶联工艺、制剂配方及ADC构建方面 ...

医药生物 2025 年 06 月 29 日 特瑞思 CD20-ADC 获突破性疗法，DLBCL 末线 mOS 或超预期，关注珍宝岛 投资要点： 行 业 定 期 报 告 行情回顾：本周（2025 年 6 月 23 日- 2025 年 6 月 27 日）中信医药指 数上涨 1.5%，跑输沪深 300 指数 0.5pct，在中信一级行业分类中排名第 24 位；2025 年初至今中信医药生物板块指数上涨 7.0%，跑赢沪深 300 指数 7.3pct，在中信行业分类中排名第 12 位。本周涨幅前五的个股为：神州细 胞（+30.5%）、浩欧博（+27.1%）、华人健康（+26.0%）、迈威生物（+17.4%）、 南模生物（+ 16.5%）。 周专题：百亿 DLBCL 市场迎来 ADC 新药，关注特瑞思（珍宝岛参 股子公司）。DLBCL 是常见的侵袭性非霍奇金淋巴瘤，占所有 NHL 的约 30%至 40%；大多数 DLBCL 进展较快，属于急危重症，需要医疗快速干 预。一线治疗早期为 CHOP 方案，治愈率为 30-35%；利妥昔单抗问世后成 为 DLBCL 治疗史上的里程碑，现阶段 R-CHOP 一线标准治疗方案已广泛 ...

Core Viewpoint - The company has made significant licensing agreements that enhance cash flow and pave the way for future commercialization of its products, including the injection of Agonist α and IL-11 targeted therapy drugs [1][2]. Group 1: Financial Impact - The total upfront payments from the two transactions amount to over 560 million RMB (3.8 billion + 250 million), which alleviates the company's financial pressure, with an estimated cash balance of approximately 1.23 billion RMB in 2024 [2]. - The agreements include a maximum total transaction amount of 500 million RMB and a tiered royalty percentage based on net sales, which will further support the company's financial health [1]. Group 2: Technological Validation - The two business development targets (8MW0511 and 9MW3811) are self-developed by the company, validating its long-acting fusion protein technology and LALA modification technology's competitive edge [3][4]. - 8MW0511 is the first approved long-acting G-CSF in China, utilizing albumin fusion technology to avoid the toxicity risks associated with PEG modification, demonstrating low immunogenicity and high production efficiency [3]. - 9MW3811 employs LALA modification technology to reduce potential toxicity risks and has shown a long half-life in clinical data, indicating significant market potential in diseases like pulmonary fibrosis [4]. Group 3: Core Assets and Future Potential - The company possesses a proprietary technology platform in the ADC field, with multiple targets and new payloads, showing promising clinical data in combination therapies [5]. - In the TCE field, the company is optimizing target selection and spatial design to reduce cytokine release syndrome (CRS) risks, with preclinical models demonstrating significant tumor suppression effects [5]. - Collaborations with AI companies are being utilized to accelerate target screening and evaluation, enhancing the company's research capabilities [5]. Group 4: Revenue Forecast - The company projects revenues of 851 million, 1.514 billion, and 2.08 billion RMB for 2025-2027, with year-on-year growth rates of 325.97%, 77.91%, and 37.38% respectively [6]. - The expected net profit for the same period is projected to be -591 million, -280 million, and 104 million RMB, with growth rates of 43.4%, 52.65%, and 137.14% respectively [6].

Summary of Innovent Biologics Update / Briefing Company Overview - **Company**: Innovent Biologics (01801) - **Event**: Healthy China 2030 Oncology Innovation Summit and R&D Day - **Date**: June 27, 2025 Key Points Industry Context - The oncology sector is a major health threat globally, affecting individuals regardless of socioeconomic status [10][14] - The biomedicine industry in China has evolved significantly over the past decade, transitioning from generics to innovative biologics [15][20] Company Achievements - Innovent was established in 2011 and has launched 16 products, with over 20 in R&D [21][22] - The company has invested over ¥8 billion (approximately $1.2 billion) and holds 20% of China's total biologics production capacity [21][22] - In 2024, Innovent's total revenue exceeded ¥9.4 billion (approximately $1.4 billion) [24] Market Position - Innovent is a leader in several oncology segments, including PD-1, VEGF, and CD20, with three of the top ten oncology drugs in China coming from Innovent [24] - The company has made significant strides in drug accessibility and affordability, with prices for monoclonal antibodies now a fraction of those in the U.S. [17][18] Future Outlook - By 2027, Innovent aims to achieve product revenue of ¥20 billion (approximately $3 billion) and to be among the top five in sales revenue in China's biopharma sector [26][40] - The company plans to have five assets in global MRCT Phase III trials by 2030 [30][41] R&D Innovations - Innovent is focusing on next-generation technologies, including new generation immuno-oncology (IO) and antibody-drug conjugates (ADC) [32][37] - The company is developing IBI-363, a PD-1 IL-2 fusion protein, which shows promise in enhancing anti-tumor immunity [36] - Collaborations with multinational firms like Roche, Eli Lilly, and Sanofi are ongoing to enhance R&D capabilities [21][22] Challenges and Opportunities - Despite progress, there are still unmet clinical needs in oncology, and Innovent aims to address these through innovative therapies [47][49] - The company is optimistic about the potential of ADCs combined with IO therapies to improve treatment outcomes for lung cancer and other malignancies [93][94] Conclusion - Innovent Biologics is positioned as a key player in the Chinese biopharma landscape, with a strong focus on innovation and collaboration to drive future growth in oncology treatments [49][50]

Summary of Whitehawk Therapeutics Fireside Chat - June 26, 2025 Company Overview - Whitehawk Therapeutics, formerly known as Adi Bioscience, underwent a transformation completed in Q1 2025, focusing on developing an advanced ADC (antibody-drug conjugate) portfolio after selling its mTOR inhibitor product to Kaken Pharmaceuticals for $100 million [3][4][15]. Pipeline and Technology - The company is developing a three-asset ADC portfolio targeting various cancers, including lung, ovarian, and gastrointestinal cancers, with a focus on established tumor biology and clinically validated tumor markers [4][5][14]. - All three programs are currently in preclinical stages, with IND (Investigational New Drug) filings anticipated by mid-2026 [6][13]. - The ADC platform utilizes a linker payload technology designed for greater stability, reduced off-target toxicity, and improved therapeutic index [5][12][13]. Key Programs 1. **HAWK 007 (PTK7-targeted ADC)** - PTK7 is broadly overexpressed in various solid tumors, with expression rates of 60-70% in cancer patients [20][21]. - The program aims to demonstrate differentiation from previous compounds, with a focus on lung cancer, ovarian cancer, and triple-negative breast cancer [24][26]. - Initial phase one trials will target patients with moderate to high expression of PTK7, aiming for a minimum response rate of 40% in lung cancer and 50% in ovarian cancer [56]. 2. **HAWK 016 (MUC16-targeted ADC)** - MUC16 is a circulating biomarker in ovarian cancer, with the approach focusing on targeting the membrane-bound portion to avoid complications from circulating biomarkers [60][63]. - The program will initially focus on gynecological cancers, with potential expansion into pancreatic and non-small cell lung cancers in the future [70]. 3. **HAWK 206 (SEZ6-targeted ADC)** - This program is in the early stages, with a biparatopic approach aimed at enhancing internalization and efficacy in neuroendocrine tumors and small cell lung cancer [71][78]. Competitive Landscape - The ADC market is competitive, with other companies like Zymeworks and Day One Pharmaceuticals developing next-generation ADCs. Whitehawk believes its platform offers superior optimization in terms of linker stability, hydrophilicity, and therapeutic index [36][46]. - The company aims to differentiate its products by demonstrating better efficacy and safety profiles compared to existing therapies [30][46]. Financial Position and Future Outlook - Whitehawk started Q2 2025 with approximately $185 million in cash, providing operational runway into early 2028 to generate clinical data before seeking additional funding [88][90]. - The company plans to release more preclinical data in 2026, focusing on a comprehensive view of its products' potential before public disclosures [89][90]. Conclusion - Whitehawk Therapeutics is positioned to make significant advancements in the ADC space with its innovative platform and targeted therapies. The upcoming IND filings and clinical trials will be critical in validating its approach and establishing its market presence.

BeiGene (BGNE) Update / Briefing June 26, 2025 08:30 AM ET Speaker0 Hello, everyone. Welcome to b one medicine's twenty twenty five investor research and development day. My name is Liza Heaps. I'm senior director of investor relations at b one. We are very excited to host our investor event today, both in person in New York City and online for our global attendees. Thank you all very much for joining us. This is truly an exciting time at b one, and we are thrilled to walk you through recent progress to dat ...

2025 年皮肤病药物品牌推荐 创新药物探秘，精准匹配患者需求 | 一、市场背景 | | 2 | | --- | --- | --- | | 1.1 摘要 | | 2 | | 1.2 皮肤病药物定义 | | 2 | | 1.3 市场演变 | | 2 | | 二、市场现状 | | 3 | | 2.1 市场规模 | | 3 | | 2.2 市场供需 | | 3 | | 三、市场竞争 | | 4 | | 3.1 市场评估维度 | | 4 | | 3.2 市场竞争格局 | | 5 | | 3.3 十大品牌推荐 | | 5 | | 四、发展趋势 | | 7 | | 4.1 技术革新将成为核心驱动力 | | 7 | | 4.2 竞争格局方面，本土企业将凭借渠道优势和创新升级巩固主导地位 | | 7 | | 4.3 政策与资本共振将加速产业升级 | | 7 | 2025 年皮肤病药物品牌推荐 一、市场背景 1.1 摘要 皮肤病药物行业专注于治疗皮肤疾病，产品多样，市场需求强劲。行业受高监管壁垒 和政策影响大，但患者需求增长驱动市场扩容。预计未来市场规模将持续增长，新型 外用治疗方式的获批将推动行业进一步发展，如科笛集团等企 ...

全球医药巨头正将中国实验室变成新药"弹药库"。 近日，荣昌生物宣布将旗下自主研发的产品泰它西普有偿许可给美国纳斯达克上市公司VorBiopharma Inc.（下称"Vor Bio"），Vor Bio将获得泰它西普在除大中华区以外的全球范围内开发、生产和商业化的 独家权利；而荣昌生物将获得4500万美元的首付款和价值8000万美元的认股权证，交易未来总金额最高 可达42.3亿美元。 无独有偶，石药集团也在近期宣布与全球制药巨头阿斯利康达成战略研发合作，收获1.1亿美元预付 款，未来潜在总收益更是高达53.3亿美元。 这只是中国创新药企"吸金"狂潮的冰山一角。据不完全统计，仅5月就有至少6家中国药企官宣BD大 单。尤其是三生制药在宣布60亿美元合作后，股价单日暴涨32%，子公司三生国健更是连续两天涨停。 投资者紧盯公告，迫切想知道：下一张巨额支票会开给谁？ 巨头"扫货"中国，半年豪掷数百亿美元 "今年可以说是中国生物科技BD大规模爆发的元年。"新加坡祥峰投资集团中国基金合伙人刘天然在第 九届医药创新与投资大会上指出，"在2021年之前，首付款能达5000万美元就算非常出色的头部交易。 如今，无论是管线交易还是后 ...

the day you retire from basketball, every studio show is going to ask you to join their show. Would you consider doing that. Oh, for sure.Um, I've seen guys, you know, some of your peers gone through it. Uh, you know, a lot of XNBA guys who are behind the booth now, whether it's commentating, whether it's in studio, you've seen what Tom Brady's doing in, you know, Draymond's going to do it the day he retires, too. Draymond's already got Yeah.his path set up. I'm going be more patient, I think, about what wo ...